ITOS vs. EWTX, SDGR, BHVN, ETNB, ANIP, JANX, EVO, MESO, VERA, and OCUL
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs. Its Competitors
Edgewise Therapeutics (NASDAQ:EWTX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.
Edgewise Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
In the previous week, Edgewise Therapeutics had 18 more articles in the media than iTeos Therapeutics. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 1 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.93 beat Edgewise Therapeutics' score of 0.52 indicating that iTeos Therapeutics is being referred to more favorably in the news media.
Edgewise Therapeutics has higher earnings, but lower revenue than iTeos Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Edgewise Therapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 207.46%. iTeos Therapeutics has a consensus target price of $15.86, suggesting a potential upside of 56.07%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Edgewise Therapeutics is more favorable than iTeos Therapeutics.
97.2% of iTeos Therapeutics shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
iTeos Therapeutics' return on equity of -21.37% beat Edgewise Therapeutics' return on equity.
Summary
Edgewise Therapeutics and iTeos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 7/2/2025 by MarketBeat.com Staff